Dr. David B. Ross, M.D.

Board Certified Neurology | Medical Director, Head R&D

David B. Ross, M.D.

PERSONAL AND PROFESSIONAL

Business Affiliation

Since 1985

Address

David B. Ross, M.D., P.A.

Owner/ President

4330 W. Broward Blvd., Ste. G

Plantation, Florida  33317

Comprehensive NeuroBehavioral Institute, PLLC

Medical Director/ CEO/ Owner

4330 W. Broward Blvd., Ste. G

Plantation, Florida  33317

NeuroPAS Global, LLC

Medical Director

4330 W. Broward Blvd., Ste. G

Plantation, Florida  33317

Date of Birth

April 23, 1953

Certification

Board Certified – American Academy of Psychiatry and Neurology

Board Eligible – Electromyography

Licensure

Florida ME-41982

Tax ID Number

27-1628716

NPI Number

1063630861

Hospital Affiliations and Appointments

Plantation General Hospital

401 N.W. 42nd Avenue

Plantation, Florida  33317

Education

1971-1975                             The Johns Hopkins University

Baltimore, Maryland

B.A Degree/Biology

1975-1979 University of Miami School of Medicine

  Miami, Florida

Post Doctoral Training

    1. Internal Medicine           University of Miami

Miami, Florida

1980-1983 Resident (Neurology)

The Longwood Area Training Program,

Harvard Medical School, Boston, Massachusetts

1982-1983      Chief Resident (Neurology) The Longwood Area Training Program

Harvard Medical School, Boston, Massachusetts

Academic Honors

High School Valedictorian, 1971

Graduated Johns Hopkins Phi Beta Kappa, 1975

Current Professional Organizations

American Medical Association

American Academy of Neurology

Broward County Medical Association

Research Affiliation

Since 2000

Sunrise Medical Research, Inc

4620 N. State Road 7

Building H, Suite 101

Lauderdale Lakes, FL 33319

Tel: 954-915-9991

Fax: 954-915-9963

Basic Science Research Experience

1972-1973  Independent research with Karl Sandhoff, Ph.D.  (Max Planck Institute) while he was on sabbatical at The John Hopkins University

    1.   Independent research as assistant to Saul Roseman, Ph.D.;Chairman,        Department of Biology, The Johns Hopkins University
    2.   Independent research with Robert A Davidoff, M.D., Department of Neurology, University of Miami School of Medicine

1978             Research with Maria Valdez Dapena, M.D., Department of Pathology,

University of Miami School of Medicine

    1.     Independent Research with Marc Dichter, M.D., Ph.D., Department of

                    Neurology, Children’s Hospital Medical Center, Boston

Research Experience

Grants or Investigator Awards

1983-1984         Muscular Dystrophy Association Fellowship

1992-1994        Investigator, The Felbamate Compassionate Use Protocol 

    Wallace Pharmaceutical Company

    1. Investigator, The Cognex Phase III Drug Study

1994-1995              Investigator, DHE Nasal Spray Phase III Drug Study

                                    Sandoz Pharmaceutical Company

1995-1996                Investigator, The Contact Phase IV Drug Study

                                    Park-Davis Pharmaceutical Company

1996-1997                 Sub investigator, Cervene Stroke Treatment Study

                                    Baker-Norton Pharmaceutical Company

1996-1998 Investigator, GAIN2 Stroke Treatment Study

                                    GlaxoWellcome Pharmaceutical Company   

    1. Investigator, GAINAMERICA Stroke Treatment Study

GlaxoWellcome Pharmaceutical Company

    1. Investigator, GAINSIX Stroke Treatment Study

                                   GlaxoWellcome Pharmaceutical Company

    1. Investigator, GAINASIST  Stroke Treatment Study

                                   GlaxoWellcome Pharmaceutical Company

1999-2001                 Investigator, BRAVO Stroke Prevention Study

Smith-Kline Beecham Pharmaceutical Company

    1. Sub-Investigator, Lamictal Trial for Painful HIV Neuropathy

                                   GlaxoWellcome Pharmaceutical Company

2000-2002                 Sub-Investigator, Conivaptan Hyponatremia Study

                                   Parke-Davis Pharmaceutical Company

    1. Investigator, KEEPER Epilepsy Study

                                   UCB Pharmaceutical Company

2001-2003                Investigator, ARTIST Stroke Study

                                   Yamanouchi Pharmaceutical Company

    1. A Phase III, Randomized, Double-Blind, Placebo-Controlled,        

                                   Outpatient Study to Assess the Efficacy and Safety of a Modified   

                                    Release Formulation of NBI-34060 in Elderly Primary Insomnia      

                                    Patients with Sleep Maintenance Difficulties (NBI-34060-MR-0217)

2002-2003                A Phase III, Open-Label, Outpatient, Extension Study to Assess the

                                   Long-Term Safety of a Modified Release Formulation of NBI-34060 in Elderly Primary Insomnia Patients with Sleep Maintenance

                                   Difficulties (NBI-34060-MR-0217)

2003-2004                 A Phase III, Randomized, Double-Blind, Placebo-Controlled,              

                                   Outpatient Study to Assess the Long-Term Safety and Efficacy of     

                                   Two Dose Levels of a Modified Release Formulation of NBI-34060 in

                                   Adult Patients with Primary Insomnia (NBI-34060-MR-0211)

2003-2004                  A Phase III, Open-label, Outpatient, Extension Study to

                                   Assess the Long-Term Safety of a Modified Release   

                                   Formulation of NBI-34060 in Adult Primary Insomnia 

                                    Patients with Sleep Maintenance Difficulties (NBI-34060-MR-0220)

    1. Phase III, Randomized, Double-Blind, Placebo-Controlled,                                                              

                                   Outpatient Study to Assess the Efficacy and Safety of a Modified   

                                   Release Formulation of NBI-34060 in Adult Primary Insomnia

                                   Patients with Sleep Maintenance Difficulties (NBI-34060-MR-0221)                      

    1.             Fourteen-Week Placebo-Controlled Dose-Response Efficacy and        

                                  Safety Study of NS 2330 in Early Parkinson’s Disease Patients (Study

                                    for Proof of Concept in Early Parkinson’s Disease of a Triple       

                                    Reuptake Inhibitor, NS 2330 / SCEPTRE)”

2003-2004 An Open-Label Multicenter Study to Assess the Safety of AVP- 923 (Dextromethorphan/Quinidine) in the Treatment of Patients with Pseudobulbar Affect

  1.   A Randomized, Open-Label Study of the Tolerability of Three Local    

                                   Anesthetic Formulations in Conjunction with NGX 4010 for the   

                                    Treatment of Neuropathic Pain

2004                            MEM-MD-20: “A Randomized, Double-Blind, Placebo-Controlled,         
                                    Flexible-Dose Study Of The Efficacy And Safety Of Memantine In  
                                    Comparison To Gabapentin In Patients With Postherpetic Neuralgia”

2004- 2008                  9.159 – PRoFESS – Prevention Regimen For Effectively avoiding   

                                     Second Strokes: A double-blind, active and placebo controlled study     

                                    of Aggrenox vs. clopidogrel,  with and without Micardis

2005-March 06            Protocol A0081059-  A Six-Month, Double-blind, Placebo-    

                                    Controlled, Durability of Effect Study of Pregabalin for Pain   

                                    Associated with Fibromyalgia

2005-July 06               A Multicenter, Randomized, Double-Blind,  Parallel-Group, Placebo-   

                                    Controlled, Efficacy,  Safety and Tolerability Study of Dronabinol    

                                    MDI  in the Acute Treatment of Migraine Headache.

2006- March 2009 A Randomized, Double Blind, Placebo-Controlled, Safety and Efficacy Study of Xyrem® (Sodium oxybate) in Subjects with Fibromyalgia

2006-2007                  Randomized, Double-Blind Study Comparing the Safety and Efficacy of the Lidocaine Patch 5% with Placebo in Patients with Pain from Carpal Tunnel  Syndrome

2008-2010             A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group,

Phase 3 Study of MAP0004 in Adult Migraineurs for a Single Migraine Followed by Open -Label Extensions to 26/52 Weeks” Protocol: MAP/P301

2008-2010            A Phase 2, Randomized, Double-blind, Placebo- and Active-comparator

                                     controlled Study of the Safety and Efficacy of LY2624803 in Outpatients with Insomnia”, Protocol I2K-MC-ZZAD

2009-2010                   “A randomized, double-blind, placebo-controlled, parallel group study evaluating the efficacy and tolerability of oral SLC022 300mg TID, a Glial cell modulating agent, versus placebo in the treatment of post herpetic neuralgia

2009-2010           “Cervical Dystonia- Patient Registry for Observation of Botox

                                    Efficary.(CDProbe)”

**********************

Since 2010:

A Phase III, Open-Label, Outpatient, Extension Study to Assess the

Long-Term Safety of a Modified Release Formulation of NBI-34060 in

Elderly Primary Insomnia Patients with Sleep Maintenance

Difficulties (NBI-34060-MR-0217)

A Phase III, Randomized, Double-Blind, Placebo-Controlled,

Outpatient Study to Assess the Long-Term Safety and Efficacy of

Two Dose Levels of a Modified Release Formulation of NBI-34060 in

Adult Patients with Primary Insomnia (NBI-34060-MR-0211)

A Phase III, Open-label, Outpatient, Extension Study to

Assess the Long-Term Safety of a Modified Release

Formulation of NBI-34060 in Adult Primary Insomnia

Patients with Sleep Maintenance Difficulties (NBI-34060-MR-0220)

Phase III, Randomized, Double-Blind, Placebo-Controlled,

Outpatient Study to Assess the Efficacy and Safety of a Modified

Release Formulation of NBI-34060 in Adult Primary Insomnia

Patients with Sleep Maintenance Difficulties (NBI-34060-MR-0221)

Fourteen-Week Placebo-Controlled Dose-Response Efficacy and

Safety Study of NS 2330 in Early Parkinson’s Disease Patients (Study

for Proof of Concept in Early Parkinson’s Disease of a Triple

Reuptake Inhibitor, NS 2330 / SCEPTRE)”

An   Open-Label   Multicenter   Study   to   Assess   the   Safety   of   AVP-  923

(Dextromethorphan/Quinidine) in the Treatment of Patients with Pseudobulbar Affect

A Randomized, Open-Label Study of the Tolerability of Three Local

Anesthetic Formulations in Conjunction with NGX 4010 for the

Treatment of Neuropathic Pain

A Randomized, Double-Blind, Placebo-Controlled,  Flexible-Dose Study Of The Efficacy And Safety Of Memantine In Comparison To Gabapentin In Patients With Postherpetic Neuralgia”

Prevention Regimen For Effectively avoiding Second Strokes: A double-blind, active and placebo controlled study of Aggrenox vs. clopidogrel,  with and without Micardis

A Six-Month, Double-blind, Placebo- Controlled, Durability of Effect Study of Pregabalin for Pain Associated with Fibromyalgia

A Multicenter, Randomized, Double-Blind,  Parallel-Group, Placebo-Controlled, Efficacy,   Safety and Tolerability Study of Dronabinol MDI  in the Acute Treatment of Migraine Headache

A Randomized, Double Blind, Placebo-Controlled, Safety and Efficacy Study of Xyrem®

(Sodium oxybate) in Subjects with Fibromyalgia  “Randomized, Double-Blind Study Comparing the Safety and Efficacy of the Lidocaine Patch 5% with Placebo in Patients with Pain from Carpal Tunnel  Syndrome”

“A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of MAP0004 in  Adult Migraineurs for a Single Migraine Followed by Open -Label Extensions to 26/52 Weeks”

A Phase 2, Randomized, Double-blind, Placebo- and Active-comparator controlled Study of the Safety and Efficacy of LY2624803 in Outpatients with Insomnia”,

“A Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy and Efficacy and Tolerability of Oral SLC022, a Glial Cell Modulating Agent verus Placebo in the Treatment of Post Herpetic Neuralgia

“Cervical Dystonia- Patient Registry for Observation of Botox Efficary.(CDProbe)”

“A Double Blind, Randomized, Vehicle-Controlled, Parallel-Group Evaluation of Civamide (Zucapsaicin) 0.01% and Vehicle Nasal Sprays in the Treatment of Postherpetic Neuralgia of the Trigeminal Nerve”

“A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 in Subjects with Pain Associated with Fibromyalgia.

“An Open-Label Extension Study of DS-5565 For 52 Weeks in Pain

Associated with Fibromyalgia.”

“A phase III Safety and Efficacy Study of ALZT-OP1 in Subjects with Evidence of Early Alzheimer’s Disease”

“Registry of Amyloid Positive Patients for Alzheimer’s Disease Drug Research

Trials (RAmP)”

“Longitudinal Cohort Study of Resource use and Cost of Mild Cognitive Impairment and

Mild Dementia due to Alzheimer’s Disease in the United States”

“A Phase 2b,  Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-

finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients with Symptomatic

Gastroesophageal Reflux Disease Not Completely Responsive to Proton Pump Inhibitors”

“A Phase 2a, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study Evaluating

The Efficacy, Safety, Tolerability, And Pharmacokinetics Of Sage-217 Oral Solution In The

Treatment Of Subjects With Essential Tremor (ET)”

Academic, Consultant or Advisory Positions

    1. Instructor, Department of Neurology, University of Miami

                              School of Medicine

    1.   Director of Special Services, Amyotrophic Lateral Sclerosis Clinic

                              University of Miami School of Medicine

    1. Medical Advisory Board, Dade-Broward Lupus Foundation
    2. Medical Advisory Board, Epilepsy Association of Broward County
    3.   Director of Head Trauma Unit, West Gables Rehabilitation Hospital
    4.     Co-director of Chronic Pain Unit, West Gables Rehabilitation Hospital
    5. Consultant, Galen Pharmaceutical Company

1988-1997           Consultant, University of Louisville Veteran’s Administration Hospital Chronic Pain Program

1990- 1995           Consultant, Phylomed Pharmaceutical Company

1995- 2001     Clinical Instructor, (1st and 2nd year students)

1999-2000       Medical Director, University Rehabilitation Center of America

2000- 2001            Medical Director, Hollywood Adult Day Care Center

2000- 2003            Director of Neuro-rehabilitation St. John’s Rehabilitation and Nursing Center

Awards

  1. Modern Marvels Invent Now Challenge: Honorable mention in the 2006 Modern Marvels Invent Now Challenge for an exceptional invention idea, Presented by Invent Now, TIME magazine, and The History Channel for the Neuro-Autonmic Testing System.

Bibliography and Presentations

Bibliography

  1. Hackman JC, Ross DB and Davidoff RA. (1978): Some actions of Catechol on synaotic transmission in the isolated spinal cord of the frog. Brain Research 157:47-61.
  2. Valdes-Dapena MA, Amazon KA, Gillane MM. Ross DB and Catherman R (1980): The question of the right ventricular hypertrophy in Sudden Infant Death Syndrome.  Arch Pathol Lab Med103: 184-186.
  3. Valdes-Dapena MA, Gillane MM, Ross DB and Catherman R (1979): Extramedullary hematopoiesis in the liver in Sudden Infant Death Syndrome.  Arch Pathol Lab Med 103: 513-515.
  4. Valdes-Dapena MA, Gillane MM, Cassady JC, Ross DB and Catherman R (1980): Wall thickness of small pulmonary arteries. Its measurement in victims of Sudden Infant Death Syndrme.  Arch Pathol Lab Med 104: 621-624.
  5. Berger JB and Ross DB (1981): Reversible Parkinson’s syndrome complicating post operative hypoparathyroidism.   Neurology 31: 881-883.
  6. Sotrel A, Rosen S, Ross DB and Ronthal M (1983): Subacute sclerosing Panencephalitis: “an immune complex disease”? Neurology 33: 885-887.
  7. Ross DB, Fischer J, Konkol S and Jones HR (1983):  Isolated radial nerve palsy in the newborn. Neurology33: 1354-1355.
  8. Ross DB, Varipapa RJ (1989): Treatment of Painful Diabetic Neuropathy with topical capsaicin.  New England Journal of Medicine 321: 474-475.
  9. Chad DA, Aronin N, Ross DB, and et.al, (1990): “(Does capsaicin relieve the pain of diabetic neuropathy?)” Pain 42: 387-388.
  10. Pfeifer M, Jung RN, Ross DB. Et.al. (1993): A Highly Successful Model for the treatment of Painful Diabetic Neuropathy.  Diabetic Research.
  11. Ross DB. A Primer on the Interpretation of Neurodiagnostic Studies (in preparation).
  12. Ross DB. “Peripheral Neuropathy – A Common Medical Entity.” PositiveVoices.  Volume 4, Issue 1. (1999).
  13. Michelle Falcone, Kemal O. Yariz, David B. Ross, Joseph Foster II, Ibis Menendez, Mustafa (2013) “ An Amino Acid Deletion inSZT2 in a Family with Non-

Syndromic Intellectual Disability” PLOS ONE December 2013 | Volume 8 | Issue 12 | e82810

Presentations

  1. Grand Rounds: Facial dysmorphism in the evaluation of Infantile Seizures. Harvard Medical School, 1983.
  2. Grand Rounds: Differential diagnosis of dementia associated with abnormal eye movements. University of Miami School of Medicine.  1983.
  3. Lecture: New Advances in the diagnosis of dementia.  National Neuroscience Congress of Argentine (“SemcosinII”), Guest lecturer 1986.
  4. Lecture: Elecrodiagosis of radiculopathy.  National Neuroscience Congress of Argentine (“Semcosin II”), Guest lecturer 1986.
  5. Lecture (with Gustavo Roman, M.D.): Advances in the treatment of Parkinson’s disease.  National Neuroscience Congress of Argentine (“Semcosin II”), Guest Lecturer 1986.
  6. Lecture: Clinical model for treatment of painful peripheral diabetic Neuropathy.  American Canadian Pain Society Annual Meeting, 1988.
  7. Lecture: A clinical model for the treatment of chronic pain.  University of Louisville Medical Center, 1989.
  8. Lecture: Treatment of chronic pain.  University of Louisville Affiliated Hospitals, 1990.
  9. Lecture: Trigger point therapy as part of a total approach to the Management of chronic pain.  University of Louisville Veteran’s Administration Hospital, 1991.
  10. Lecture: Myofacial pain syndrome in the post-operative pain after hand Surgery.  University of Louisville Affiliated Hospitals, 1992.
  11. Moderator: Natonal Teleconference.  New advances in the treatment of Multiple sclerosis.  Hollywood, Florida, 1993.
  12. Moderator: International Teleconference.  The role of Felbatol in the Management of refratory seizures.  San Juan, Puerto Rico, 1993.
  13. Lecture: The uses and abuses of neurodiagnostic testing.  State Farm Insurance Company, Fort Lauderdale, Florida, 1995.
  14. Lectures: The use of Aricept in the treatment of Alzheimer’s disease.
  15. Speaker for Pfizer Pharmaceutical Company. 1997-1998.
  16. Lecture. The diagnosis and treatment of Alzheimer’s disease.  The West Broward Alzheimer’s Support Group, 1997.
  17. Lecture.  The use of Maxalt n the treatment of migraine headaches. 
  18. Speaker for Merck Pharmaceutical Company, 1999.
  19. Lecture. Advances in the Treatment of Stroke-Brain Atack.  Speaker for Plantation General Hospital.  2000.
  20. TV appearance. Advances in the Treatment of Stroke-Brain Attack.
  21. Speaker for Plantation General Hospital.  2000.
  22. Radio talk. Advances in the Headache.  Speaker for Hollywood Medical 2000.
  23. Lecture. Treatment of Dementia.  Speaker for Janssen Pharmaceutical Company, Destin, Florida.  2001.
  24. Speaker on pain conditions and a new Interventional Pain Assessment Tool at the IASP ( International Association for the Study of Pain) conference Tennessee, USA. 2009.
  25. Presentation on a new Interventional Pain Assessment Tool at Johns Hopkins University Baltimore, Maryland. 2010.
  26. Presentation on a new Interventional Pain Assessment Tool at the Mayo Clinic Rochester, Minnesota. 2010.
  27. Presentation on a new Interventional Pain Assessment Tool at Harvard University 2010.
  28. Presentation on a new Interventional Pain Assessment Tool at Dalhousie University Halifax, Nova Scotia. 2010.
  29. Presentation on “Changing Concepts of Pain: Increasing the Role of the Behavioral Health Professional” at the Mental Health Association of Southeast Florida. 2013
  30. Presentation on “Neurophysiologic Pain Profile – a tool for evaluating pain.”  Spine 10 x 25 Summit. 2016

    

He is the creator of the NP3, is a leading expert in neuropathy and pain management. He graduated from Johns Hopkins University and the University of Miami School of Medicine. He completed post-doctoral training in Internal Medicine at the University of Miami; and his residency in Neurology at Harvard Medical School where he was a Chief Resident – Neurology from 1982 to 1983. He is Board Certified as a member of the American Academy of Psychiatry and Neurology.

Dr. Ross completed independent research with Saul Roseman, Ph.D., Chairman of Biology, Johns Hopkins University Medical Center and with Karl Sandhoff, Ph.D. of the Max Planck Institute. He served as a faculty member for the University of Miami before beginning private practice, and he is a published expert in the area of neuropathy.

Dr. Ross is a member of the American Medical Association, the American Academy of Neurology, the New York Academy of Science and the American Association for the Advancement of Science. Dr Ross has participated in numerous basic science research projects; and has received numerous research grants and investigator awards.

He has served as an expert witness in litigation matters, as a neurological expert in chronic pain, and has given many presentations on a variety of medical subjects.